Methods and compositions for simulating a dermal compartment of skin are disclosed. In one aspect of the invention, methods of producing such a skin model include the steps of admixing a collagenous protein source, a blood protein source, and dermal cells in an aqueous carrier, and then allowing the resulting mixture to solidify to produce a gel. In one technique, at least a portion of the mixture, e.g., the collagenous protein source is first heated and then cooled to induce gelation. For example, the mixture can be heated to at least 50 degrees C. and then cooled to temperature below 5 degrees C. to induce gelation.

The present disclosure provides methods for monitoring inflammation in ALS and other related diseases. Therapeutic interventions based on the results of monitoring methods are also provided.

Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

Safe, rapid and efficient methods for producing antigen-specific T cells recognizing human papilloma virus or HPV antigens.

The invention relates to a method for the resolution of pro-tumour inflammation by means of a pharmaceutical preparation. Leukocytes are isolated from the buffy coat obtained from whole blood and a portion of the leukocytes is placed in a first pouch receiving a differentiation factor and stored in conditions that preserve cellular viability for several days, before a defined, fresh culture medium is supplied, after which said leukocyte portion is left to rest for a further several days, which results in the production of macrophages. A further portion of the leukocytes is placed in a second pouch and irradiated therein. The two pouches are then mixed and the supernatant is recovered to serve as pharmaceutical preparation. The invention also relates to the use in the treatment of cancers, either alone or in combination with other therapies, in human and veterinary medicine.

The present invention provides processes for producing a bioengineered lung (BEL) from an acellular lung matrix that has been treated with growth hormones, seeded with primary lung cells, and cultured in a bioreactor. Also provided are BELs and methods of transplanting the BEL into a subject in need of a lung transplant, and methods for using BELs for the study of the lung microbiome and its role in lung development and remodeling.

The present disclosure provides methods for assessing and optimizing cellular quality of a cell-based therapy that is being produced in an automated cell engineering system. The methods suitably include monitoring molecular characteristics of the cells before, during, and after the automated process to provide feedback to the process parameters. In embodiments, the cells being produced are Chimeric Antigen Receptor (CAR) T-cells.

The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.

Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.

Cell culture systems and methods provide improved immunotherapeutic product manufacturing with greater scalability, flexibility, and automation. Cell culture systems are configured with interchangeable cartridges, allowing versatility and scalability. Systems are configured to have multiple connected cell culture chambers, which allows parallel processing of different types of cells. Gas-impermeable cell culture chambers and methods for generating cells in closed systems prevent contamination and user error. Methods for recycling cell culture medium provide additional efficiencies.